Table 1.
Baseline demographic data of the progression and the non-progression groups
| Variables |
Progression Group (n = 198) |
Non-progression Group (n = 168) | p value |
|---|---|---|---|
| Age |
65.83 ± 11.46 |
64.74 ± 10.19 |
0.375 |
| Sex(Man/Women) |
158/40 |
139/29 |
0.474 |
| BMI (kg/m2) |
25.47 ± 3.18 |
24.80 ± 3.63 |
0.421 |
| Hypertension (%) |
153 (77.3) |
121 (72.5) |
0.289 |
| Diabetes (%) |
85 (42.9) |
51 (30.4) |
0.013 |
| NGR (%) |
67 (33.8) |
86 (51.2) |
0.001 |
| IFG (%) |
13 (6.6) |
7 (4.2) |
0.362 |
| IGT (%) |
20 (10.1) |
18 (10.8) |
0.865 |
| IFG + IGT (%) |
13 (6.6) |
6 (3.6) |
0.241 |
| Initial admission n (%) |
|
|
|
| ECG abnormalities |
24 (12.1) |
12 (7.1) |
0.111 |
| Stable Angina |
29 (14.6) |
33 (19.6) |
0.204 |
| Unstable Angina |
86 (43.4) |
70 (41.7) |
0.733 |
| Non-ST elevated AMI |
10(5.1) |
9(5.4) |
0.895 |
| ST elevated AMI |
49 (24.7) |
44 (26.2) |
0.752 |
| Medication (%) |
|
|
|
| Statin |
196 (99.5) |
165 (98.8) |
0.468 |
| CCB |
67(29.6) |
55(32.9) |
0.806 |
| ACEI/ARB |
104 (53.6) |
76 (46.1) |
0.154 |
| β-blocker |
164 (82.8) |
128(76.6) |
0.141 |
| Oral glucose lowering dug |
70(35.9) |
35(21.2) |
0.002 |
| Application of insulin | 9(4.5) | 11(6.5) | 0.491 |